As important from Adam's STAT article (missed it if was mentioned on SRPT call) is they will modify the study and go for approval on the one trial (I speculated as such on twitter on more than one occasion)!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.